KTC
TXMD icon

Kistler-Tiffany Companies’s TherapeuticsMD TXMD Stock Holding History

Kistler-Tiffany Companies’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-20
Closed -$5K – 565
2017
Q2 		$5K Hold
20
– – ﹤0.01% 441
2017
Q1 		$7K Hold
20
– – ﹤0.01% 426
2016
Q4 		$6K Hold
20
– – ﹤0.01% 440
2016
Q3 		$7K Hold
20
– – ﹤0.01% 457
2016
Q2 		$9K Hold
20
– – ﹤0.01% 435
2016
Q1 		$6K Hold
20
– – ﹤0.01% 453
2015
Q4 		$10K Hold
20
– – 0.01% 450
2015
Q3 		$6K Hold
20
– – ﹤0.01% 484
2015
Q2 		$8K Buy
+20
New +$7.06K ﹤0.01% 480

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Kistler-Tiffany Companies's TXMD Position: Q3 2017 in Review

Kistler-Tiffany Companies sold out of TherapeuticsMD (TXMD) in Q3 2017, closing a stake of 20 shares — an estimated $5K sold.

Kistler-Tiffany Companies first reported a position in TXMD in Q2 2015 and held it in 9 quarters. The position peaked at $10K in Q4 2015. 134 funds tracked by Wall St. Rank hold TXMD as of Q3 2017.

  • Kistler-Tiffany Companies reported no remaining TherapeuticsMD position as of Q3 2017 after selling out during the quarter.
  • Kistler-Tiffany Companies sold 20 TherapeuticsMD shares in Q3 2017, an estimated $5K.
  • Kistler-Tiffany Companies first reported a position in TherapeuticsMD in Q2 2015 and held it in 9 quarters.
  • Kistler-Tiffany Companies's TherapeuticsMD position peaked at $10K in Q4 2015.
  • 134 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2017.

Based on Kistler-Tiffany Companies's 13F filing for Q3 2017, filed 19 Oct 2017.